These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36875313)

  • 1. Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma.
    Kurashina R; Ando K; Inoue M; Maruyama R; Mitani K; Takenobu H; Haruta M; Onuki R; Matsuoka Y; Kamijo T; Kageyama Y
    Cancer Diagn Progn; 2023; 3(2):230-235. PubMed ID: 36875313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.
    Yamamoto Y; Yatsuda J; Shimokawa M; Fuji N; Aoki A; Sakano S; Yamamoto M; Suga A; Tei Y; Yoshihiro S; Kitahara S; Nagao K; Takai K; Kamiryo Y; Akao J; Yamaguchi S; Oba K; Shimabukuro T; Matsumoto H; Kamba T; Matsuyama H
    Int J Clin Oncol; 2021 Jan; 26(1):169-177. PubMed ID: 32948925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma.
    Kurashina R; Ando K; Inoue M; Izumi K; Maruyama R; Mitani K; Takenobu H; Haruta M; Iizuka T; Kamijo T; Kageyama Y
    Anticancer Res; 2022 Feb; 42(2):1131-1136. PubMed ID: 35093916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma.
    Kadono Y; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kamijima T; Seto C; Takano A; Yotsuyanagi S; Nakagawa R; Miyagi T; Aoyama S; Asahi H; Fukuda R; Mizokami A
    Anticancer Res; 2021 Mar; 41(3):1599-1606. PubMed ID: 33788755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
    Sato R; Inamoto T; Matsushita Y; Takemura A; Uchimoto T; Sano A; Tanaka H; Ishikawa G; Watanabe K; Watanabe H; Tamura K; Motoyama D; Sugiyama T; Otsuka A; Harada KI; Azuma H; Miyake H
    Int J Urol; 2023 Sep; 30(9):730-736. PubMed ID: 36575640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
    Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
    Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
    Ksienski D; Wai ES; Alex D; Croteau NS; Freeman AT; Chan A; Patterson T; Clarkson M; Fiorino L; Poonja Z; Fenton D; Irons S; Lesperance M
    Transl Lung Cancer Res; 2021 Jan; 10(1):355-367. PubMed ID: 33569318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
    Sonpavde G; Pond GR; Fougeray R; Choueiri TK; Qu AQ; Vaughn DJ; Niegisch G; Albers P; James ND; Wong YN; Ko YJ; Sridhar SS; Galsky MD; Petrylak DP; Vaishampayan UN; Khan A; Vogelzang NJ; Beer TM; Stadler WM; O'Donnell PH; Sternberg CN; Rosenberg JE; Bellmunt J
    Eur Urol; 2013 Apr; 63(4):717-23. PubMed ID: 23206856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
    Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab.
    Akashi Y; Yamamoto Y; Hashimoto M; Adomi S; Fujita K; Kiba K; Minami T; Yoshimura K; Hirayama A; Uemura H
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors and Reference Markers of Treatment Options for Locally Advanced Squamous Cell Carcinoma Located in the Middle and Upper Esophagus.
    Wang C; Tong J; Tang M; Lu Y; Liang G; Zhang Z; Chen T
    Cancer Manag Res; 2021; 13():1075-1085. PubMed ID: 33574705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
    Ito K; Kobayashi T; Kojima T; Hikami K; Yamada T; Ogawa K; Nakamura K; Sassa N; Yokomizo A; Abe T; Tsuchihashi K; Tatarano S; Inokuchi J; Tomida R; Fujiwara M; Takahashi A; Matsumoto K; Shimizu K; Araki H; Kurahashi R; Osaki Y; Tashiro Y; Uegaki M; Ogawa O; Kitamura H; Nishiyama H
    Cancer Med; 2021 May; 10(10):3188-3196. PubMed ID: 33931987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemoglobin, albumin, lymphocyte, and platelet score and neutrophil-to-lymphocyte ratio are novel significant prognostic factors for patients with small-cell lung cancer undergoing chemotherapy.
    Yang N; Han X; Yu J; Shu W; Qiu F; Han J
    J Cancer Res Ther; 2020 Sep; 16(5):1134-1139. PubMed ID: 33004760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
    Ando K; Kurashina R; Motoi N; Iizuka T; Inoue M; Maruyama R; Mitani K; Takenobu H; Haruta M; Onuki R; Matsuoka Y; Kamijo T; Kageyama Y
    Biochem Biophys Res Commun; 2023 Oct; 676():165-170. PubMed ID: 37517219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.